Johnson & Johnson launched the VARIPULSE Pro Platform in Europe following CE Mark approval. The device utilizes pulsed field ablation (PFA) to treat atrial fibrillation (AFib).
AFib is the most common heart rhythm disorder and affects over 50 million people globally. The new platform integrates with the existing CARTO 3 System for 3D heart mapping to enable precise treatment.
The technology aims to improve procedure efficiency while maintaining safety and effectiveness. The VARIPULSE Pro is not currently approved for use in the United States.